MentionFox
Home › Executive changes › Veracyte, Inc.
Leadership changes · VCYT · SEC Form 8-K, Item 5.02

Leadership changes at Veracyte, Inc. (2026)

Before you join, sell to or invest in Veracyte, Inc.

MentionFox check on Veracyte, Inc.: only 1 source on file so far (checked 15 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/veracyte

Check Veracyte, Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Veracyte, Inc.?

Who joined and who left Veracyte, Inc. (VCYT)? 1 appointment reported on 2026-03-16, each cited to the company's own filing.

Kevin Haas was named Chief Development and Technology Officer of Veracyte, Inc., effective March 24, 2026. As of November 15, 2026, Veracyte, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on March 16, 2026, naming 1 appointment (Form 8-K, March 16, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

Artisan Partners Asset Management Inc. also filed stake reports on 17 other companies ↓

Sell to companies like Veracyte, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes1
In (appointed)1
Latest filing2026-03-16

Veracyte, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-03-16. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Veracyte, Inc. files it.

Also on the record for Veracyte, Inc.

DateRecordFigureOur pageSource
November 12, 2026Stake report, Schedule 13G/A, by Artisan Partners Asset Management Inc.2.9% of the class5%+ stakesSource
November 5, 2026Stake report, Schedule 13G/A, by FMR LLC7.7% of the class5%+ stakesSource
September 14, 2026Acquired Convergent Genomics Inc.$150MAcquisitionSource
June 5, 2026Stake report, Schedule 13G/A, by FMR LLC10.1% of the class5%+ stakesSource
May 13, 2026Stake report, Schedule 13G/A, by Artisan Partners Asset Management Inc.6.9% of the class5%+ stakesSource
May 12, 2026Stake report, Schedule 13G, by STATE STREET CORPORATION6.3% of the class5%+ stakesSource
May 6, 2026Stake report, Schedule 13G/A, by FMR LLC9.7% of the class5%+ stakesSource
April 30, 2026Stake report, Schedule 13G, by Vanguard Capital Management5.2% of the class5%+ stakesSource
April 29, 2026Stake report, Schedule 13G, by Vanguard Portfolio Management5.67% of the class5%+ stakesSource
March 27, 2026Stake report, Schedule 13G/A, by The Vanguard Group—5%+ stakesSource
February 5, 2026Stake report, Schedule 13G/A, by FMR LLC7.2% of the class5%+ stakesSource
February 3, 2026Stake report, Schedule 13G/A, by Artisan Partners Asset Management Inc.7.9% of the class5%+ stakesSource

Selling to them or working with them? See who runs Veracyte, Inc. now and the warning signs.

Free to see. No signup.

Keep reading

More on Veracyte, Inc. and the records around it.

Veracyte, Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on Veracyte, Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Veracyte, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Veracyte, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    13 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The newest 12 of 20 records.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-03-16InChief Development and Technology Officer2026-03-248-K, 2026-03-16

Who leads Veracyte, Inc., as last reported?

For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.

Selling to Veracyte, Inc.?

New leaders reset buying decisions — get the Full Report on Veracyte, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Veracyte, Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the Chief Development and Technology Officer at Veracyte, Inc., with the record behind each one.

Find candidates like Chief Development and Technology Officer at Veracyte, Inc.

Every change, in the filing's words

Filed 2026-03-16 · 8-K

Appointed: Kevin Haas, Chief Development and Technology Officer, effective 2026-03-24

On March 16, 2026, Veracyte, Inc. (the "Company") announced the appointment of Dr. Kevin Haas, 40, as its Chief Development and Technology Officer, effective March 24, 2026.

Also stated in this filing

  • Prior to joining the Company, Dr. Haas served as Chief Technology Officer of Myriad Genetics, Inc. (NASDAQ: MYGN), a genetic testing and precision medicine company, a position he held since February 2021.
  • Previously, Dr. Haas served as Senior Vice President of Technology and Senior Vice President of Engineering at Myriad and as Vice President and Senior Director of Bioinformatics at Myriad Women's Health.
  • Dr. Haas received a B.S. in Chemical Engineering from the University of Wisconsin-Madison and a Ph.D. in Chemical Engineering from the University of California, Berkeley.
  • The equity awards will be granted under the Company's 2023 Equity Incentive Plan and the applicable award agreements.

Tools for this story

Each opens in a new tab, filled in for Veracyte, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/veracyte
Last updated 2026-11-15
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Who joined Veracyte, Inc.? Leadership changes (2026). MentionFox, 2026-11-15. https://mentionfox.com/executive-changes/veracyte